1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS
申请人:Rano Thomas
公开号:US20070265304A1
公开(公告)日:2007-11-15
The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
[EN] 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS<br/>[FR] DÉRIVÉS DE 1,2,3,4-TÉTRAHYDRO-QUINOLINE EN TANT QU'INHIBITEURS DE LA CETP
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2008079427A1
公开(公告)日:2008-07-03
[EN] The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them. [FR] La présente invention concerne des composés de formule (I) décrits ici comme étant utiles en tant qu'inhibiteurs de la CETP, des compositions les contenant, et des procédés pour les utiliser.
Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform
作者:Thomas A. Rano、Ellen Sieber-McMaster、Patricia D. Pelton、Maria Yang、Keith T. Demarest、Gee-Hong Kuo
DOI:10.1016/j.bmcl.2009.03.051
日期:2009.5
a potent inhibitor of the cholesterol ester transfer protein (CETP), a target for the treatment of low HDL-C and atherosclerosis. Low HDL-C has been identified as a key risk factor for cardiovascular disease in addition to high LDL-C, the target of the statin drugs. Tetrahydroquinoline A inhibits partially purified CETP with an IC50 of 39 nM. The preparation of a series of potent inhibitors of CETP